Gemini Therapeutics (NASDAQ:GMTX) and Petros Pharmaceuticals (NASDAQ:PTPI) Head to Head Comparison

Insider & Institutional Ownership

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 8.2% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Gemini Therapeutics and Petros Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87 million	($1.00)	-70.80
Petros Pharmaceuticals	$5.11 million	0.04	-$8.16 million	($1.64)	0.00

Petros Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.

Profitability

This table compares Gemini Therapeutics and Petros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Summary

Petros Pharmaceuticals beats Gemini Therapeutics on 5 of the 9 factors compared between the two stocks.

About Gemini Therapeutics

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.